Abstract
Purpose
To report two cases of intractable superior limbic keratoconjunctivitis (SLK) treated with bevacizumab and triamcinolone injection.
Case summary
A 69-year-old female visited our clinic with pain in the left eye for 3 days and was diagnosed with SLK in her left eye. After 3 months of using steroid eye drops, artificial tears, and oral steroid intermittently, there was no improvement in symptoms and signs, thus this case was considered intractable with the conventional therapy. A mixture of bevacizumab (0.15 cc) and triamcinolone (0.05 cc) was injected into the sub-tenon’s capsule of the left eye. After 1 week, all symptoms and signs disappeared, and there was no recurrence for 6 months. A 55-year-old female was transferred to our clinic due to SLK that did not respond to artificial tears, steroid eye drops, punctal occlusion, and botox injection for 3 months. A mixture of bevacizumab (0.15 cc) and triamcinolone (0.05 cc) was injected into the sub-tenon’s capsule of the left eye. After 2 weeks, all symptoms and signs were improved, and there was no recurrence for 4 months.
References
2. Confino J, Brown SI. Treatment of superior limbic keratoconjunctivitis with topical cromolyn sodium. Ann Ophthalmol. 1987; 19:129–31.
3. Sahin A, Bozkurt B, Irekec M. Topical cyclosporine a in the treatment of superior limbic keratoconjunctivitis: a long-term fol-low-up. Cornea. 2008; 27:193–5.
4. Chun YS, Kim JC. Treatment of superior limbic keratoconjunctivitis with a large-diameter contact lens and Botulium Toxin A. Cornea. 2009; 28:752–8.
5. Shen YC, Wang CY, Tsai HY, Lee YF. Supratarsal triamcinolone injection in the treatment of superior limbic keratoconjunctivitis. Cornea. 2007; 26:423–6.
6. Yang HY, Fujishima H, Toda I, et al. Lacrimal punctal occlusion for the treatment of superior limbic keratoconjunctivitis. Am J Ophthalmol. 1997; 124:80–7.
7. Sun YC, Hsiao CH, Chen WL, et al. Conjunctival resection combined with tenon layer excision and the involvement of mast cells in superior limbic keratoconjunctivitis. Am J Ophthalmol. 2008; 145:445–52.
8. Udell IJ, Kenyon KR, Sawa M, Dohiman CH. Treatment of superior limbic keratoconjunctivitis by thermocauterization of the superior bulbar conjunctiva. Ophthalmol. 1986; 93:162–6.
9. Kojima T, Matsumoto Y, Ibrahim OM, et al. In vivo evaluation of superior limbic keratoconjunctivitis using laser scanning confocal microscopy and conjunctival impression cytology. Invest Ophthalmol Vis Sci. 2010; 51:3986–92.
10. Kadrmas EF, Bartley GB. Superior limbic keratoconjunctivitis. A prognostic sign for severe Gravesophthalmopathy. Ophthalmol. 1995; 102:1472–5.
11. Matsuda A, Tagawa Y, Matsuda H. TGF-beta2, tenascin, and in-tegrin beta1 expression in superior limbic keratoconjunctivitis. Jpn J Ophthalmo. 1999; 43:251–6.
12. Cher I. Superior limbic keratoconjunctivitis: multifactorial me-chanical pathogenesis. Clin Experiment Ophthalmol. 2000; 28:181–4.
14. Kojima T, Matsumoto Y, Ibrahim OM, et al. In vivo evaluation of superior limbic keratoconjunctivitis using laser scanning confocal microscopy and conjunctival impression cytology. Invest Ophthalmol Vis Sci. 2010; 51:3986–92.
15. Jackson JR, Seed MP, Kircher CH, et al. The codependence of an-giogenesis and chronic inflammation. FASEB J. 1997; 11:457–65.
16. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004; 3:391–400.
17. Nakao S, Zandi S, Lara-Castillo N, et al. Larger therapeutic win-dow for steroid versus VEGF-A inhibitor in inflammatory angio-genesis: surprisingly similar impact on leukocyte infiltration. Invest Ophthalmol Vis Sci. 2012; 53:3296–302.
18. Oh JY, Kim MK, Shin MS, et al. The anti-inflammatory effect of subconjunctival bevacizumab on chemically burned rat corneas. Curr Eye Res. 2009; 34:85–91.
19. Wershil BK, Furuta GT, Lavigne JA, et al. Dexamethasone and cyclosporin A suppress mast cell-leukocyte cytokine cascades by multiple echanisms. Int Arch Allergy Immunol. 1995; 107:323–4.
20. Itakura H, Akiyama H, Hagimura N, et al. Triamcinolone acetonide suppresses interleukin-1 beta-mediated increase in vascular endothelial growth factor expression in cultured rat Muller cells. Graefes Arch Clin Exp Ophthalmol. 2006; 244:226–31.
21. Ferrante P, Ramsey A, Bunce C, Lightman S. Clinical trial to compare efficacy and side-effects of injection of posterior sub-Tenon triaet al. mcinolone versus orbital floor methylprednisolone in the management of posterior uveitis. Clin Exp Ophthalmol. 2004; 32:563–8.